Skip to content

Adherence Evaluation in COPD

Evaluation of Perception and Knowledge of Adherence to COPD Inhalation Therapy at Patient, GP and Pulmonologist Level

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04246931
Enrollment
260
Registered
2020-01-29
Start date
2020-01-01
Completion date
2020-06-30
Last updated
2020-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence, Treatment, COPD

Brief summary

The rationale of this study is to have a better understanding of the perception of the pulmonologists, general practitioners and patients of adherence (causes, main consequences, supportive tools,..) and the use of TAI-questionnaire (appreciation, usability,…) by interviewing pulmonologists & general practitioners and a survey with patients. Based on the outcome, projects and tools can be developed to help health care professionals to motivate patients to improve adherence and to help patients to increase their adherence to inhalation therapy.

Interventions

OTHERNo intervention (survey)

No intervention -\> survey at 1 timepoint

Sponsors

Chiesi SA/NV
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL

Inclusion criteria

Pulmonologists or general practitioners or COPD patient (suffering from COPD treated with inhalation therapy)

Exclusion criteria

Not applicable

Design outcomes

Primary

MeasureTime frameDescription
Knowledge and perception of adherenceBaselineGathering knowledge based on semi-structured interview (definition, causes, consequences of bad adherence,...)

Secondary

MeasureTime frameDescription
Test of the adherence to inhalers-questionnaire (TAI)BaselineEvaluate the usability of 'Test of the adherence to inhalers'-questionnaire (TAI) based on semi-structured interview

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026